[ back to News ]

CoNCERT Pharmaceuticals Strengthens Executive Leadership Team: Appoints Jeffrey Williams as Chief Business Officer, Promotes Nancy Stuart to Chief Operating Officer

December 13, 2007

LEXINGTON, MASS.— Concert Pharmaceuticals, Inc.™, the first company dedicated to creating novel medicines utilizing the naturally-occurring element deuterium, announced today the promotion of Nancy Stuart to the role of Chief Operating Officer and the appointment of Jeffrey Williams to the newly created position of Chief Business Officer.

“We are delighted to welcome Jeff to our organization and to recognize Nancy’s significant contributions to the successful launch of CoNCERT,” stated Roger Tung, Ph.D., President and Chief Executive Officer of CoNCERT. “We believe that CoNCERT’s application of deuterium chemistry in drug discovery and development represents a fundamental advance in the creation of new medicines and has enabled us to attract a top-notch leadership team and leading investors. We believe that our platform will allow both greatly reduced R&D timelines and enhanced likelihood of successful clinical development. Through focused execution on our R&D strategy, we have made notable progress with our pipeline of proprietary new chemical entities (NCEs) this year, and expect to enter the clinic with our first of several development candidates in 2008.”

In her new role as Chief Operating Officer, Ms. Stuart will be responsible for operations management, while overseeing a broad range of tactical, operational and development activities. She has over 20 years of experience in the biotechnology and pharmaceutical industry and most recently served as CoNCERT’s Senior Vice President, Corporate Strategy and Operations. Prior to CoNCERT, she held senior business and drug development positions in large and small biotechs and clinical development companies including Amgen Inc., Vertex Pharmaceuticals, Inc. and Genzyme Corp. Ms. Stuart received her M.B.A. from the Simmons College Graduate School of Management and her B.S. from the University of Michigan.

As Chief Business Officer, Mr. Williams will be responsible for managing business development activities, as well as strategic planning and manufacturing efforts. He brings to CoNCERT more than 18 years of experience working in the biotechnology and pharmaceutical industry and most recently held the position of Senior Vice President, Operations and Manufacturing at Alexza Pharmaceuticals, Inc. Prior to Alexza, he held senior operations and business development positions at Vertex Pharmaceuticals, Inc. Mr. Williams received his M.S. from the M.I.T. Sloan School of Management and his B.A. from Brigham Young University.

About CoNCERT

CoNCERT Pharmaceuticals is the first company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. CoNCERT applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. CoNCERT expects to initiate its first clinical study in the second half of 2008. More information on CoNCERT can be found on the Company’s website at http://www.concertpharma.com.

[ back to top ]